{"id":"sufentanil-sublingual-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201163","moleculeType":"Small molecule","molecularWeight":"578.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sufentanil activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing rapid onset analgesia. The sublingual tablet formulation allows for quick absorption through the oral mucosa, providing faster pain relief compared to oral administration. It is approximately 500-1000 times more potent than morphine.","oneSentence":"Sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:57.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain management in opioid-tolerant patients"},{"name":"Breakthrough pain in cancer patients"}]},"trialDetails":[{"nctId":"NCT04959812","phase":"PHASE1, PHASE2","title":"Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Healthy","enrollment":46},{"nctId":"NCT05288348","phase":"PHASE3","title":"DSUVIA Early Evaluation of Pain Trial","status":"COMPLETED","sponsor":"Frank Guyette","startDate":"2022-08-05","conditions":"Traumatic Injury","enrollment":150},{"nctId":"NCT06917651","phase":"PHASE3","title":"Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-04-22","conditions":"Pain Management","enrollment":300},{"nctId":"NCT04263909","phase":"PHASE4","title":"The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":"Spine Fusion, Pain, Postoperative, Opioid Use","enrollment":199},{"nctId":"NCT04561375","phase":"PHASE4","title":"Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-12-11","conditions":"Knee Arthroscopy","enrollment":61},{"nctId":"NCT04432428","phase":"PHASE4","title":"Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-05-26","conditions":"Postoperative Pain","enrollment":90},{"nctId":"NCT05259098","phase":"PHASE4","title":"Morphine vs Sufentanil PCA: Same Same or Different?","status":"COMPLETED","sponsor":"Hospital Central do Funchal","startDate":"2019-10-01","conditions":"Analgesia, Post Operative Pain, Patient Satisfaction","enrollment":54},{"nctId":"NCT04448457","phase":"NA","title":"Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Tivoli","startDate":"2017-09-01","conditions":"Postoperative Pain","enrollment":72},{"nctId":"NCT03036514","phase":"NA","title":"Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery.","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2017-04-05","conditions":"Pain, Postoperative","enrollment":27},{"nctId":"NCT03403842","phase":"NA","title":"Acute Post-operative Pain in Colon Resections","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2018-02-01","conditions":"Analgesia","enrollment":159},{"nctId":"NCT02662764","phase":"PHASE3","title":"Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2016-09-28","conditions":"Moderate-to-severe Acute Pain","enrollment":320},{"nctId":"NCT02447848","phase":"PHASE3","title":"Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2015-10","conditions":"Moderate-to-severe Acute Pain","enrollment":76},{"nctId":"NCT02662556","phase":"PHASE3","title":"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2016-03","conditions":"Acute Moderate-to-severe Pain","enrollment":140},{"nctId":"NCT02356588","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2015-02","conditions":"Post-Operative Pain","enrollment":161}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zalviso"],"phase":"marketed","status":"active","brandName":"Sufentanil Sublingual Tablet","genericName":"Sufentanil Sublingual Tablet","companyName":"Centre Hospitalier Universitaire de Tivoli","companyId":"centre-hospitalier-universitaire-de-tivoli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sufentanil Sublingual Tablet is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist drug. It is used to treat conditions such as analgesia, postoperative pain, moderate-to-severe acute pain, and postoperative pain, as studied in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}